摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-氯-1,2,3,4-四氢喹啉 | 49716-18-9

中文名称
6-氯-1,2,3,4-四氢喹啉
中文别名
——
英文名称
6-chloro-1,2,3,4-tetrahydroquinoline
英文别名
——
6-氯-1,2,3,4-四氢喹啉化学式
CAS
49716-18-9
化学式
C9H10ClN
mdl
MFCD09034966
分子量
167.638
InChiKey
PASUADIMFGAUDB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    41 °C
  • 沸点:
    125-127 °C(Press: 3 Torr)
  • 密度:
    1.162±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2933499090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    2-8°C

SDS

SDS:e36aff5827cfe33e2bc0c0376d6e2f41
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 6-Chloro-1,2,3,4-tetrahydroquinoline
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloro-1,2,3,4-tetrahydroquinoline
CAS number: 49716-18-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H10ClN
Molecular weight: 167.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-氯-1,2,3,4-四氢喹啉2,6-二甲基吡啶 作用下, 以 甲醇 为溶剂, 反应 2.5h, 生成 N,N-二甲基-3-苯基丙烷-1-胺
    参考文献:
    名称:
    光电昂德1,2,3,4- Tetrahydroquinolinium盐的降解
    摘要:
    结果表明,1,1-二甲基-1,2,3,4- tetrahydroquinolinium离子经历,直接照射下通过在CH石英3 OH和独立的平衡离子的性质(I -,BF),的还原裂解N(1)–C(8a)键(光Emde降解)。以高收率形成相应的N,N-二甲基-3-苯基丙胺,而没有被四氢喹啉鎓盐的霍夫曼降解产物污染。C(2)处的Me基团以及C(6)处的取代基(CH 3,Cl,CH 3 O)有利于光Emde降解。在光反应过程中,芳族Cl-取代基被还原分离。
    DOI:
    10.1002/hlca.19850680721
  • 作为产物:
    描述:
    1-乙酰-1,2,3,4-四氢喹啉盐酸磺酰氯 作用下, 以 四氯化碳乙醇 为溶剂, 反应 4.0h, 生成 6-氯-1,2,3,4-四氢喹啉
    参考文献:
    名称:
    Forced nucleophilic substitution reaction of chlorobenzenes bearing electron-donating groups by the use of "naked" methoxide anion.
    摘要:
    氯苯的亲核芳香取代反应与甲氧基阴离子的反应即使在同一芳香环中存在电子给体基团的情况下也能顺利进行,这是在氯苯通过铬三羰基配合物激活,并且通过使用18-冠-6增强甲氧基阴离子的有效性时进行的。随后,对该方法在吲哚啉或四氢喹啉体系中的应用进行了研究,并成功将5-氯-1, 3, 3-三甲基吲哚啉转化为相应的5-甲氧基或5-苄氧基化合物。
    DOI:
    10.1248/cpb.28.3639
点击查看最新优质反应信息

文献信息

  • [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
    申请人:BIOMARIN PHARM INC
    公开号:WO2020257487A1
    公开(公告)日:2020-12-24
    Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
    本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物,以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法,例如与甘氧酸氧化酶(GO)或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱,例如原发性高草酸尿症。
  • Ruthenium(II)-Catalyzed Regioselective C-8 Hydroxylation of 1,2,3,4-Tetrahydroquinolines
    作者:Changjun Chen、Yixiao Pan、Haoqiang Zhao、Xin Xu、Zhenli Luo、Lei Cao、Siqi Xi、Huanrong Li、Lijin Xu
    DOI:10.1021/acs.orglett.8b02926
    日期:2018.11.2
    Ru(II)-catalyzed chelation-assisted highly regioselective C8-hydroxylation of 1,2,3,4-tretrahydroquinolines has been developed. Various 1,2,3,4-tetrahydroquinolines underwent smooth C8–H hydroxylation with cheap and safe K2S2O8 as the oxidant and oxygen source to furnish the corresponding products in good to excellent yields with high tolerance of the functional groups. The choice of a readily installable
    已经开发了Ru(II)催化的1,2,3,4-四氢喹啉的螯合辅助的高区域选择性C8-羟基化反应。各种1,2,3,4-四氢喹啉经过顺畅的C8–H羟基化反应,并以廉价且安全的K 2 S 2 O 8作为氧化剂和氧源,以高收率和高官能度耐受性提供了相应的产品。选择易于安装和拆卸的N-嘧啶导向基团是催化的关键。机理研究表明六元循环中间体参与了催化循环。该方法还可以扩展到其他(杂)芳烃CH键的直接羟基化反应。
  • A General Catalyst Based on Cobalt Core–Shell Nanoparticles for the Hydrogenation of N‐Heteroarenes Including Pyridines
    作者:Kathiravan Murugesan、Vishwas G. Chandrashekhar、Carsten Kreyenschulte、Matthias Beller、Rajenahally V. Jagadeesh
    DOI:10.1002/anie.202004674
    日期:2020.9.28
    core–shell based nanoparticles prepared by template synthesis of cobalt‐pyromellitic acid on silica and subsequent pyrolysis. The optimal catalyst material allows for general and selective hydrogenation of pyridines, quinolines, and other heteroarenes including acridine, phenanthroline, naphthyridine, quinoxaline, imidazo[1,2‐a]pyridine, and indole under comparably mild reaction conditions. In addition
    在此,我们报道了通过二氧化硅均苯四酸的模板合成和随后的热解制备的特定二氧化硅负载的Co/Co 3 O 4核壳纳米粒子的合成。最佳的催化剂材料允许在相对温和的反应条件下对吡啶喹啉和其他杂芳烃(包括吖啶咯啉、啶、喹喔啉咪唑并[1,2-a]吡啶吲哚)进行全面和选择性氢化。此外,还展示了这些纳米颗粒的回收利用及其脱氢催化能力。
  • Formal Deoxygenative Hydrogenation of Lactams Using PN<sup>H</sup>P-Pincer Ruthenium Complexes under Nonacidic Conditions
    作者:Osamu Ogata、Hideki Nara、Kazuhiko Matsumura、Yoshihito Kayaki
    DOI:10.1021/acs.orglett.9b03878
    日期:2019.12.20
    amides to amines with RuCl2(NHC)(PNHP) (NHC = 1,3-dimethylimizadol-2-ylidene, PNHP = bis(2-diphenylphosphinoethyl)amine) is described. Various secondary amides, especially NH-lactams, are reduced with H2 (3.0-5.0 MPa) to amines at a temperature range of 120-150 °C with 1.0-2.0 mol % of PNHP-Ru catalysts in the presence of Cs2CO3. This process consists of (1) deaminative hydrogenation of secondary amides
    描述了用RuCl2(NHC)(PNHP)(NHC = 1,3-二甲基亚甲基吲哚-2-亚基,PNHP =双(2-二苯基膦基乙基)胺)将酰胺进行正式的脱氧加氢成胺。在Cs2CO3存在下,在1.0-2.0 mol%的PNHP-Ru催化剂下,在120-150°C的温度范围内,用H2(3.0-5.0 MPa)将各种仲酰胺(尤其是NH-内酰胺)还原为胺。该方法包括(1)仲酰胺的脱基加氢生成伯胺和醇,(2)瞬态胺与醇的脱氢偶联生成亚胺,(3)亚胺的加氢生成形式上脱氧的仲胺产物。
  • Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot–Marie–Tooth Type 2A Mouse Model
    作者:Sida Shen、Cristina Picci、Kseniya Ustinova、Veronick Benoy、Zsófia Kutil、Guiping Zhang、Maurício T. Tavares、Jiří Pavlíček、Chad A. Zimprich、Matthew B. Robers、Ludo Van Den Bosch、Cyril Bařinka、Brett Langley、Alan P. Kozikowski
    DOI:10.1021/acs.jmedchem.0c02210
    日期:2021.4.22
    we report the discovery of a new THQ-capped HDAC6i, termed SW-101 (1s), that possesses excellent HDAC6 potency and selectivity, together with markedly improved metabolic stability and druglike properties compared to SW-100 (1a). X-ray crystallography data reveal the molecular basis of HDAC6 inhibition by SW-101 (1s). Importantly, we demonstrate that SW-101 (1s) treatment elevates the impaired level
    组蛋白脱乙酰基酶6(HDAC6)是治疗神经退行性疾病的有希望的治疗靶标。SW-100(1a)是带有四氢喹啉THQ)封端基团的基于苯基异羟酸酯的HDAC6抑制剂(HDAC6i),是一种高效且选择性强的HDAC6i,已证明在脆性X综合征和Charcot–Marie–的小鼠模型中有效2A型牙齿疾病(CMT2A)。在这项研究中,我们报告发现了一种新的被THQ封端的HDAC6i,称为SW-101(1s),与SW-100(1a)相比,HDAC6i具有出色的HDAC6效能和选择性,并具有明显改善的代谢稳定性和类似药物的特性。X射线晶体学数据揭示了SW-101(1s)。重要的是,我们证明了SW-101(1s)治疗可升高坐骨神经末梢中乙酰化α-微管蛋白的受损平,抵消进行性运动功能障碍,并改善携带突变型MFN 2的CMT2A小鼠模型的神经性症状。这一结果预示着SW-101(1s)作为一种疾病缓解型HDAC6i的进一步发展。
查看更多